TUB Financière de Tubize SA
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.…
Industry Peers
BiotechnologyKey Statistics
About Financière de Tubize (EBR: TUB)
›
Financière de Tubize (EBR: TUB) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 230.60 EUR on 19 November 2026, up 16.2% over 52 weeks. Its 52-week range is 168.10 EUR to 250.50 EUR: the price is 7.9% below the high and 37.2% above the low.
At a market capitalisation of 10.26B EUR, it trades at 104.3 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a premium of 211% for TUB. It pays a dividend yielding 0.46% (it pays out 49% of its earnings), against a median of 0.94% among the dividend payers in that peer group.
Financière de Tubize reports return on equity of 4.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 49.90M EUR. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 286.00 EUR is 24.0% above the current price. The next earnings report is expected on 20 March 2027.